Metronomic capecitabine as second-line treatment for patients with hepatocellular carcinoma with preserved liver function: A phase II study.

被引：1
|
作者：
de Rosa, F.
Agostini, V.
Di Girolamo, S.
Andreone, P.
Trevisani, F.
Bolondi, L.
Pinna, A. D.
Serra, C.
Golfieri, R.
Biasco, G.
Brandi, G.
机构：
[1] Univ Bologna, Bologna, Italy
[2] Azienda Osped Bologna, Policlin S Orsola Malpighi, Bologna, Italy
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2011年 / 29卷 / 15期
关键词：
D O I：
10.1200/jco.2011.29.15_suppl.e14608
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e14608
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Phase II trial of second-line chemotherapy with docetaxel and capecitabine in advanced esophageal squamous cell carcinoma
    Li, Xuyuan
    Lin, Wen
    Wang, Hongbiao
    Lin, Wenzhao
    Lin, Suiling
    Lin, Yingcheng
    MEDICAL ONCOLOGY, 2013, 30 (04)
  • [42] Phase II study of paclitaxel combined with capecitabine as second-line treatment for advanced gastric carcinoma after failure of cisplatin-based regimens
    Baize, N.
    Abakar-Mahamat, A.
    Mounier, N.
    Berthier, F.
    Caroli-Bosc, F. X.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2009, 64 (03) : 549 - 555
  • [43] Living donor liver transplantation as a second-line therapeutic strategy for patients with hepatocellular carcinoma
    Takada, Yasutsugu
    Ueda, Mikiko
    Ito, Takashi
    Sakamoto, Seisuke
    Haga, Hironori
    Maetani, Yoji
    Ogawa, Kohei
    Kasahara, Mureo
    Oike, Fumitaka
    Egawa, Hiroto
    Tanaka, Koichi
    LIVER TRANSPLANTATION, 2006, 12 (06) : 912 - 919
  • [44] A Phase II Study of Weekly Docetaxel as Second-Line Chemotherapy in Patients With Metastatic Urothelial Carcinoma
    Kim, Young Saing
    Lee, Soon Il
    Park, Se Hoon
    Park, Silvia
    Hwang, In Gyu
    Lee, Sang-Cheol
    Sun, Jong-Mu
    Lee, Jeeyun
    Lim, Ho Yeong
    CLINICAL GENITOURINARY CANCER, 2016, 14 (01) : 76 - 81
  • [45] Defining the Ideal Patient with Hepatocellular Carcinoma for Second-Line Treatment
    Roviello, Giandomenico
    Casadei-Gardini, Andrea
    Nobili, Stefania
    Mini, Enrico
    Fancelli, Sara
    JOURNAL OF ONCOLOGY, 2020, 2020
  • [46] Targeted agents for second-line treatment of advanced hepatocellular carcinoma
    Personeni, Nicola
    Pressiani, Tiziana
    Bozzarelli, Silvia
    Rimassa, Lorenza
    WORLD JOURNAL OF GASTROINTESTINAL ONCOLOGY, 2019, 11 (10) : 788 - 803
  • [47] Targeted agents for second-line treatment of advanced hepatocellular carcinoma
    Nicola Personeni
    Tiziana Pressiani
    Silvia Bozzarelli
    Lorenza Rimassa
    World Journal of Gastrointestinal Oncology, 2019, (10) : 788 - 803
  • [48] Capecitabine (XE) plus Irinotecan (IRI) as second-line treatment (XELIRI) for metastatic colorectal cancer (MCRC) in elderly patients: Feasibility and safety results from a Phase II study.
    Fiorentini, G
    Dentico, P
    Cantore, M
    Rossi, S
    Pacetti, P
    Bernardeschi, P
    Della Seta, R
    Tumolo, S
    de Giorgi, U
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 289S - 289S
  • [49] Paclitaxel, ifosfamide, and nedaplatin as second-line treatment for patients with metastatic urothelial carcinoma: A phase II study of the SUOC group
    Kitamura, Hiroshi
    Taguchi, Keisuke
    Kunishima, Yasuharu
    Yanase, Masahiro
    Takahashi, Atsushi
    Shigyo, Masanori
    Tanaka, Toshiaki
    Mutoh, Masatoshi
    Fukuta, Fumimasa
    Masumori, Naoya
    Tsukamoto, Taiji
    CANCER SCIENCE, 2011, 102 (06) : 1171 - 1175
  • [50] Randomized phase II study of axitinib versus placebo plus best supportive care in second-line treatment of advanced hepatocellular carcinoma
    Kang, Y. -K.
    Yau, T.
    Park, J. -W.
    Lim, H. Y.
    Lee, T. -Y.
    Obi, S.
    Chan, S. L.
    Qin, S. K.
    Kim, R. D.
    Casey, M.
    Chen, C.
    Bhattacharyya, H.
    Williams, J. A.
    Valota, O.
    Chakrabarti, D.
    Kudo, M.
    ANNALS OF ONCOLOGY, 2015, 26 (12) : 2457 - 2463
12345